Minneapolis, MN, Feb. 21, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company
developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion
electrophysiology (EP) marketplace, today announced that its President & CEO, Mr. Gregory Cash will present at SeeThruEquity 3rd
Annual Innovations Investor Conference on Wednesday, February 22, 2017 at the W Hotel South Beach, Miami.
During the conference Mr. Cash will deliver the Company’s corporate presentation and discuss recent business highlights.
Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Ms. Lora Mikolaitis
lmikolaitis@biosigtech.com.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4 billion
electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of
Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System.
BioSig’s technology has been developed to address an unmet need in a large and growing market. The PURE EP System is a novel
cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during
procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia.
Data from the 2016 HRI Global Opportunities in Medical Devices & Diagnostics report shows the global Electrophysiology (EP)
market revenues will grow nearly 10% annually, from currently $4 billion to approximately $6 billion by 2020 with accompanying
procedure growth close to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020. Procedure growth in the United
States alone is projected at an 11.0% annual rate, from 250,000 in 2015 to 422,000 in 2020; accompanied by an 11.7% growth in
revenues, from $1.85 billion in 2015 to $3.220 billion in 2020.
BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance and CE Mark for the
PURE EP System. The Company has achieved proof of concept validation and tested its prototype at the University of California at
Los Angeles (UCLA) Cardiac Arrhythmia Center, and has performed pre-clinical studies at Mayo Clinic in Minnesota and Mount Sinai
Hospital in NY. The company continues to perform research and development studies in the form of an Advanced Research Program at
Mayo Clinic which began in June 2016. Other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute and
UH Case Medical Center in Cleveland also play an important role in the PURE EP technology.
Contact: Investor Relations Brian McLaughlin BioSig Technologies, Inc. bmclaughlin@biosigtech.com 917-370-9817 Robert Haag Managing Partner IRTH Communications BSGM@irthcommunications.com 866-976-4784
